Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Nelfinavir + Radiotherapy rectum cancer not applicable detail...
BRAF V600E Cetuximab rectum cancer resistant detail...
BRAF V600E Panitumumab rectum cancer resistant detail...
BRAF V600E Vemurafenib + Cetuximab + Irinotecan rectum cancer sensitive detail...
BRAF V600E Vemurafenib + Panitumumab + Irinotecan rectum cancer sensitive detail...
KRAS exon 2 Cetuximab rectum cancer resistant detail...
KRAS exon 2 Panitumumab rectum cancer resistant detail...
KRAS exon 3 Cetuximab rectum cancer resistant detail...
KRAS exon 3 Panitumumab rectum cancer resistant detail...
KRAS exon 4 Cetuximab rectum cancer resistant detail...
KRAS exon 4 Panitumumab rectum cancer resistant detail...
NRAS exon 2 Cetuximab rectum cancer resistant detail...
NRAS exon 2 Panitumumab rectum cancer resistant detail...
NRAS exon 4 Cetuximab rectum cancer resistant detail...
NRAS exon 4 Panitumumab rectum cancer resistant detail...
NRAS exon 3 Cetuximab rectum cancer resistant detail...
NRAS exon 3 Panitumumab rectum cancer resistant detail...
KRAS G12C RMC-4550 rectum cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01274624 Phase I FOLFIRI Bevacizumab + Reolysin Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Completed
NCT01309126 Phase III Cetuximab Cetuximab + Imprime PGG Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Terminated
NCT01740648 Phase I Trametinib + Fluorouracil Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting
NCT01966289 Phase I Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) Active, not recruiting
NCT01985763 Phase Ib/II Genistein Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Genistein in Treatment of Metastatic Colorectal Cancer Completed
NCT02041481 Phase I MEK162 + FOLFOX MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed
NCT02199236 Phase I Capecitabine + Fluorouracil Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management Recruiting
NCT02399813 Phase Ib/II ADXS11-001 Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum Active, not recruiting
NCT02508077 Phase II FOLFIRI Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated
NCT03127098 Phase Ib/II ALT-803 + ETBX-011 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Active, not recruiting
NCT03152370 Phase I E7046 + mFOLFOX-6 Capecitabine + E7046 Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1) Recruiting
NCT03317119 Phase I Trametinib + trifluridine/tipiracil hydrochloride Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting
NCT03516708 Phase Ib/II Pembrolizumab Epacadostat Capecitabine + Oxaliplatin Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Not yet recruiting
NCT03770689 Phase Ib/II Capecitabine Capecitabine + MSC2490484A Phase Ib/II Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer Not yet recruiting
NCT03829410 Phase Ib/II Bevacizumab + FOLFIRI + PCM-075 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Not yet recruiting